PRCT
Procept Biorobotics Corp
NASDAQ: PRCT · HEALTHCARE · MEDICAL DEVICES
$21.71
-5.73% today
Updated 2026-04-29
Market cap
$1.24B
P/E ratio
—
P/S ratio
4.01x
EPS (TTM)
$-1.72
Dividend yield
—
52W range
$19 – $67
Volume
1.8M
Procept Biorobotics Corp (PRCT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.17M | $7.72M | $34.47M | $75.01M | $136.19M | $224.50M | $308.05M |
| Revenue growth (YoY) | — | +25.1% | +346.7% | +117.6% | +81.6% | +64.8% | +37.2% |
| Cost of revenue | $8.05M | $8.97M | $18.61M | $37.93M | $65.14M | $87.40M | $111.83M |
| Gross profit | $-1.89M | $-1.25M | $15.87M | $37.09M | $71.05M | $137.10M | $196.23M |
| Gross margin | -30.6% | -16.3% | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| R&D | $13.15M | $16.27M | $18.99M | $28.98M | $48.45M | $62.30M | $71.28M |
| SG&A | $28.52M | $30.27M | $51.04M | $88.83M | $121.49M | $171.41M | $228.81M |
| Operating income | $-43.55M | $-47.80M | $-54.16M | $-80.72M | $-109.17M | $-96.61M | $-103.86M |
| Operating margin | -705.9% | -619.4% | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| EBITDA | $-39.76M | $-44.90M | $-50.72M | $-79.13M | $-98.09M | $-82.00M | $-80.11M |
| EBITDA margin | -644.5% | -581.8% | -147.1% | -105.5% | -72.0% | -36.5% | -26.0% |
| EBIT | $-41.25M | $-47.76M | $-54.04M | $-81.97M | $-101.90M | $-87.23M | $-86.50M |
| Interest expense | $724000.00 | $5.26M | $5.81M | $5.18M | $4.00M | $4.18M | $8.88M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-41.98M | $-53.02M | $-59.85M | $-87.15M | $-105.90M | $-91.41M | $-95.57M |
| Net income growth (YoY) | — | -26.3% | -12.9% | -45.6% | -21.5% | +13.7% | -4.6% |
| Profit margin | -680.4% | -687.0% | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |